SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (626)8/10/2001 6:46:07 PM
From: Miljenko Zuanic  Read Replies (2) of 717
 
If you can refresh my memory, what is primary end-point? Survival or response rate?

TIA,

Miljenko

PS: If survival is primary end-point I will not expect data before 1Q-2002. Otherwise, data may come short of the expectation.

<<Patient enrollment was completed earlier this year in a pivotal Phase III study of Xcytrin for the treatment of brain metastases, i.e., advanced stage cancer that has spread from another part of the body to the brain. Data is currently being collected and analyzed for this trial, and top line results should be available by the end of this year or early next year.>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News